Regeneron Reports 84-Week Pasatru Extension Results
In the Phase 3 OPTIMA extension, Pasatru showed zero new HO lesions from week 56 to 84 versus nine on placebo, with fewer clinician-assessed flare-ups and a generally consistent safety profile.
In the Phase 3 OPTIMA extension, Pasatru showed zero new HO lesions from week 56 to 84 versus nine on placebo, with fewer clinician-assessed flare-ups and a generally consistent safety profile.